NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and new data from phase I dose expansion showing 83% objective response rate in primary lesion.
First clinical data reported phase I immuno-oncology trial showing conversion of anti-PD-1 non-responders to responders.
Extended global capital markets presence with a successful Nasdaq IPO that provided gross proceeds of €93.5 million ($113.3 million).
Cash, cash equivalents, and short-term investments were €119.2 million at December 31, 2020, supporting robust development plans into the second quarter of 2023.
Coherent Confirms Receipt of New Acquisition Proposal from Lumentum
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Webee s No-Code End-to-End Solution Builder Software Powered by Microsoft Azure and Running on Semtech LoRa Devices Democratizes IoT – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.